Product Code: ETC052423 | Publication Date: Jan 2021 | Updated Date: Feb 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The biologics market in Mexico is witnessing significant growth, driven by advancements in healthcare and the increasing prevalence of chronic diseases. Biopharmaceuticals, including vaccines, monoclonal antibodies, and gene therapies, are gaining prominence in the market. Collaborations between pharmaceutical companies and research institutions are contributing to the development and accessibility of biologics in the country.
Advances in biotechnology, coupled with an aging population and rising healthcare awareness, are driving the biologics market in Mexico. The demand for innovative and targeted biologic therapies for various medical conditions is growing, fostering research, development, and market penetration.
The Mexico Biologics Market encounters challenges in fostering a supportive regulatory environment, ensuring affordability, and promoting research and development. Biologics, being complex and innovative therapeutic products, require clear regulatory pathways for approval and market access. Striking a balance between encouraging innovation and maintaining affordability poses a challenge for policymakers and industry stakeholders. Additionally, the market must address the need for skilled professionals in biotechnology and bioprocessing. Navigating intellectual property issues and fostering collaboration between academia, industry, and regulatory bodies are ongoing challenges in the Mexico Biologics Market.
The pharmaceutical industry in Mexico is subject to rigorous regulatory frameworks to ensure the safety and efficacy of medical products. Government policies governing the biologics market emphasize adherence to international standards and quality control measures. Regulatory approvals for biotechnological innovations and investments in research and development contribute to the expansion of the biologics market, positioning Mexico as a key player in the global pharmaceutical landscape.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Mexico Biologics Market Overview |
3.1 Mexico Country Macro Economic Indicators |
3.2 Mexico Biologics Market Revenues & Volume, 2019 & 2026F |
3.3 Mexico Biologics Market - Industry Life Cycle |
3.4 Mexico Biologics Market - Porter's Five Forces |
3.5 Mexico Biologics Market Revenues & Volume Share, By Source, 2020 & 2030F |
3.6 Mexico Biologics Market Revenues & Volume Share, By Product Type, 2019 & 2026F |
3.7 Mexico Biologics Market Revenues & Volume Share, By Disease Category, 2019 & 2026F |
3.8 Mexico Biologics Market Revenues & Volume Share, By Biologics Manufacturing, 2019 & 2026F |
4 Mexico Biologics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Mexico Biologics Market Trends |
6 Mexico Biologics Market, By Types |
6.1 Mexico Biologics Market, By Source |
6.1.1 Overview and Analysis |
6.1.2 Mexico Biologics Market Revenues & Volume, By Source, 2016 - 2026F |
6.1.3 Mexico Biologics Market Revenues & Volume, By Microbial, 2016 - 2026F |
6.1.4 Mexico Biologics Market Revenues & Volume, By Mammalian, 2016 - 2026F |
6.1.5 Mexico Biologics Market Revenues & Volume, By Others, 2016 - 2026F |
6.2 Mexico Biologics Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 Mexico Biologics Market Revenues & Volume, By Monoclonal Antibodies, 2016 - 2026F |
6.2.3 Mexico Biologics Market Revenues & Volume, By Vaccines, 2016 - 2026F |
6.2.4 Mexico Biologics Market Revenues & Volume, By Recombinant Proteins, 2016 - 2026F |
6.2.5 Mexico Biologics Market Revenues & Volume, By Antisense, RNAi, & Molecular Therapy, 2016 - 2026F |
6.2.6 Mexico Biologics Market Revenues & Volume, By Others, 2016 - 2026F |
6.3 Mexico Biologics Market, By Disease Category |
6.3.1 Overview and Analysis |
6.3.2 Mexico Biologics Market Revenues & Volume, By Oncology, 2016 - 2026F |
6.3.3 Mexico Biologics Market Revenues & Volume, By Infectious Diseases, 2016 - 2026F |
6.3.4 Mexico Biologics Market Revenues & Volume, By Immunological Disorders, 2016 - 2026F |
6.3.5 Mexico Biologics Market Revenues & Volume, By Cardiovascular Disorders, 2016 - 2026F |
6.3.6 Mexico Biologics Market Revenues & Volume, By Hematological Disorders, 2016 - 2026F |
6.3.7 Mexico Biologics Market Revenues & Volume, By Others, 2016 - 2026F |
6.4 Mexico Biologics Market, By Biologics Manufacturing |
6.4.1 Overview and Analysis |
6.4.2 Mexico Biologics Market Revenues & Volume, By Outsourced, 2016 - 2026F |
6.4.3 Mexico Biologics Market Revenues & Volume, By In-house, 2016 - 2026F |
7 Mexico Biologics Market Import-Export Trade Statistics |
7.1 Mexico Biologics Market Export to Major Countries |
7.2 Mexico Biologics Market Imports from Major Countries |
8 Mexico Biologics Market Key Performance Indicators |
9 Mexico Biologics Market - Opportunity Assessment |
9.1 Mexico Biologics Market Opportunity Assessment, By Source, 2019 & 2026F |
9.2 Mexico Biologics Market Opportunity Assessment, By Product Type, 2019 & 2026F |
9.3 Mexico Biologics Market Opportunity Assessment, By Disease Category, 2019 & 2026F |
9.4 Mexico Biologics Market Opportunity Assessment, By Biologics Manufacturing, 2019 & 2026F |
10 Mexico Biologics Market - Competitive Landscape |
10.1 Mexico Biologics Market Revenue Share, By Companies, 2023 |
10.2 Mexico Biologics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |